The intriguing future of pharmacoepidemiology

European Journal of Clinical Pharmacology

Volumn 69, Issue SUPPL. 1, 2013, Pages

  Wettermark, Björn ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Databases; Drug utilization; Future; Observational studies; Pharmacoepidemiology

Indexed keywords

PRESCRIPTION DRUG; THALIDOMIDE;

ARTICLE; CLINICAL PHARMACOLOGY; CONFIDENTIALITY; DRUG EXPOSURE; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; ENVIRONMENTAL IMPACT; EXPECTATION; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL SPECIALIST; PHARMACOEPIDEMIOLOGY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PRIVACY; SELECTION BIAS; EPIDEMIOLOGY;

BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG UTILIZATION; HUMANS; PHARMACOEPIDEMIOLOGY; PHARMACOLOGY, CLINICAL;

EID: 84886743695     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1496-6     Document Type: Article

References (74)

1. Strom BL, Kimmell SE, Hennessy S (eds) (2012) Pharmacoepidemiology, 5th edn. Wiley, Malden
2. Lawson DH (1984) Pharmacoepidemiology: a new discipline. Br Med J 289:940
3. Engel A, Siderius P (1968) The consumption of drugs. Report on a study, 1966-1967 (EURO 3101). WHO Regional Office for Europe, Copenhagen
4. Bergman U, Elmes P, Halse M, Halvorsen T, Hood M, Lunde PKM, Sjöqvist F, Wade OL, Westerholm B (1975) The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol 8:83-89
5. Sjöqvist F (1975) Drug utilization. In: Mattils MJ (ed) Proc 6th Int Congress of Pharmacology, vol 5 (clinical pharmacology). Finnish Pharmacological Society, Helsinki, pp 39-50
6. Grimsson A, Idänpään Heikkilä J, Lunde PKM, Olafsson O, Westerholm B (1979) The utilization of psychotopic drugs in Finland, Iceland, Norway and Sweden. Studies in drug utilization. WHO Regional Publications. European Series No 8. World Health Organization. Regional Office for Europe. Copenhagen
7. Stika L (1983) Patterns in drug utilization-national and international aspects: antidiabetic drugs. Acta Med Scand 105[Suppl 683]:53-57
8. WHO Drug Utilization Research Group (DURG), Griffiths K, McDevitt DG, Andrew M, Baksaas I, Lunde PK, Bergman U, Wessling A, Sjoqvist F (1985) Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol 29:1-8
9. WHO Drug Utilization Research Group (DURG), Griffiths K, McDevitt DG, Andrew M, Baksaas I, Helgeland A, Jervell J, Lunde PK, Oydvin K, Agenas I, Bergman U et al (1986) Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. Eur J Clin Pharmacol 30:513-519
10. WHO Drug Utilization Research Group (DURG), Griffiths K, McDevitt DG, Andrew M, Baksaas I, Helgeland A, Jervell J, Lunde PK, Oydvin K, Agenas I, Bergman U et al (1986) Therapeutic traditions in Northern Ireland, Norway and Sweden: II. Hypertension. Eur J Clin Pharmacol 30:521-525
11. Westerholm B (1986) Therapeutic auditing at the national and international level. Br J Clin Pharmacol 22:55S-59S
12. Stolley PD, Lasagna L (1969) Prescribing patterns of physicians. J Chron Dis 22:395-405
13. World Health Organization (WHO) (1977) The selection of essential drugs. Technical Report Series No. 615. World Health Organization, Geneva
14. World Health Organization (WHO) (2003) Introduction to drug utilisation research, NLM classification WB 330. World Health Organization, Oslo
15. Bergman U (2001) Pharmacoepidemiology-from description to quality assessment. A Swedish perspective. Norwegian J Epidemiol (Norsk Epidemiologi) 11:31-36
16. Sjöqvist F, Borgå O, Dahl M-L, Orme MLE (1997) Fundamentals of clinical pharmacology. In: Speight TM (ed) Avery's drug treatment, 4th edn. Adis Press, Auckland, pp 1-73
17. Laporte JR, Porta M, Capella D (1983) Drug utilization studies; a tool for determining the effectiveness of drug use. Br J Clin Pharmacol 16:301-304 (Pubitemid 13049163)
18. Sjöqvist F, Agenäs I (eds) (1983) Drug utilization studies: implications for medical care. Proceedings from ANIS symposium, Sånga-Säby, Sweden. Acta Med Scand 105 [Suppl 683]
19. Lee D, Bergman U (2000) Studies of drug utilization. In: Strom BL (ed) Pharmacoepidemiology, 3rd edn. John Wiley, Chichester, pp 463 - 481
20. Wettermark B, Vlahovic-Palcevski V, Salvesen Blix H, Rønning M, Vander Stichele RH (2008) Drug utilization research. In: Hartzema AG, Tilson HH, Chan KA (eds) Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti, pp 159 - 195
21. Sjöqvist F, Birkett D (2003) Drug utilization. In: Du Souich, Orme M, Erill S (eds) The IUPHAR compendium of basic principles for pharmacological research in humans. IUPHAR Pubications, Irvine, pp 76-84
22. Strom BL, Tugwell P (1990) Pharmacoepidemiology: current status, prospects, and problems. Ann Intern Med 113:179-181 (Pubitemid 20242292)
23. Alvarez-Requejo A, Porta M (1995) Pharmacoepidemiology in practice. Current status and future trends. Drug Safety 13:1-7
24. Spitzer WO (1991) Drugs as determinants of health and disease in the population. An orientation to the bridge science of pharmacoepidemiology. J Clin Epidemiol 44:823-830
25. Schoenbach VJ (2003) Understanding the fundamentals of epidemiology: an evolving text. Learning material from the Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill. Available from: http://www.epidemiolog.net/. Accessed 20 Feb 2013
26. Malcolm E, Downey W, Strand LM, McNutt M, West R (1993) Saskatchewan Health 's linkable data bases and pharmacoepidemiology. Post Market Surveill 6:175-264 (Pubitemid 23195232)
27. Saunders KW, Stergachis A, Von Korff M (1994) Group health cooperative of Puget sound. In: Strom BL (ed) Pharmacoepidemiology, 2nd edn. John Wiley & Sons, West Sussex, pp 171-185
28. Friedman GD (1994) Kaiser Permanente medical care program: Northern California and other regions. In: Strom BL (ed) Pharmacoepidemiology, 2nd edn. John Wiley & Sons, West Sussex, pp 187-197
29. Carson JL, Strom BL (1994) Medicaid databases. In: Strom BL (ed) Pharmacoepidemiology, 2nd edn. John Wiley & Sons, West Sussex, pp 199-216
30. Leufkens HG, Urquhart J (1994) Automated record linkage and other approaches to pharmacoepidemiology in the Netherlands. In: Strom BL (ed) Pharmacoepidemiology, 2nd edn. John Wiley & Sons, West Sussex, pp 231-244
31. García Rodríguez LA, Pérez Gutthann S (1998) Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45:419-425
32. Evans JM, MacDonald TM (1999) Record-linkage for pharmacovigilance in Scotland. Br J Clin Pharmacol 47:105-110 (Pubitemid 29043172)
33. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106:86-94
34. Takahashi Y, Nishida Y, Asai S (2012) Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol 68:123-129
35. European Drug Utilization Research Group (2011). European Cross-National Comparison of Drug Utilisation activities. Publication from the European scientific meeting of Drug Utilization "Better public health through pharmacoepidemiology and quality use of medicine", Antwerp, Belgium 2011. Available from: http://www.pharmacoepi.org/eurodurg/workgr/Eurodurg-meeting-CNC- 2011.pdf. Accessed 20 Feb 2013
36. PROTECT: Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (2012). Drug consumption databases in Europe. Master document, updated October 2012. Available from: http://www.imi-protect.eu/ frameworkRep.shtml. Accessed 20 Feb 2013
37. Kimura T, Matsushita Y, Yang YH, Choi NK, Park BJ (2011) Pharmacovigilance systems and databases in Korea, Japan, and Taiwan. Pharmacoepidemiol Drug Saf 20:1237-1245
38. Larsson S, Lawyer P, Garellick G, Lindahl B, Lundstrom M (2012) Use of 13 disease registries in 5 countries demonstrates the potential to use outcome data to improve health care's value. Health Aff (Millwood) 31:220-227
39. Schneeweiss S (2007) Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 82:143-156
40. Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, Gallacher J, Green J, Matthews P, Pell J, Sprosen T, Collins R, on behalf of UK Biobank (2012) UK biobank: current status and what it means for epidemiology. Health Policy Technol 1:123-126
41. Sorensen HT, Sabroe S, Olsen J (1996) A framework for evaluation of secondary data sources for epidemiological research. Int J Epidemiol 25:435-442 (Pubitemid 26137126)
42. Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58:323 -337
43. Harpe SE (2009) Using secondary data sources for pharmacoepidemiology and outcomes research. Pharmacotherapy 29:138-153
44. Begaud B (2000) Dictionnary of pharmacoepidemiology. John Wiley, Chichester
45. Porta M (ed) (2008) A dictionary of epidemiology, 5th edn. Oxford, Oxford University Press
46. Walker AM (1996) Confounding by indication. Epidemiology 7:335-336
47. Suissa S (2009) Statistical methods in pharmacoepidemiology: advances and challenges. Stat Methods Med Res 18:3-6
48. Seeger JD, Williams PL, Walker AM (2005) An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 14:465-476 (Pubitemid 40990742)
49. Concato J, Horwitz RI (2004) Beyond randomised versus observational studies. Lancet 363:1660-1661 (Pubitemid 38670319)
50. Kongsted HC, Konnerup M (2012) Are more observational studies being included in Cochrane reviews? BMC Res Notes 5:570
51. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM (2008) The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 62:76- 87
52. Wettermark B, Jacobsson B, Godman B, Haaijer-Ruskamp F (2009) Soft regulations in pharmaceutical policymaking -an overview of current approaches and their consequences. Appl Health Econ Health Policy 7:1-11
53. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H et al (2011) Bridging the efficacy-effectiveness gap: a regulator 's perspective on addressing variability of drug response. Nat Rev Drug Discov 10:495-506
54. European Medicines Agency (2005) The European Medicines Agency 's (EMA) guideline on risk management systems for medicinal products for human use. European Medicines Agency, London
55. The U.S. Food and Drug Administration Amendments Act of 2007. http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/Significant AmendmentstotheFDCAct/ FoodandDrugAdministration AmendmentsActof2007/default.htm. Accessed 20 March 2013
56. Hallas J, Støvring H (2006) Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 98:260-265
57. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska O, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Haycox A, Garattini S, Gustafsson LL (2010) Risk sharing arrangements for pharmaceuticals: potential and recommendations for European payers. BMC Health Serv Res 10:153
58. Avorn J, Fischer M (2010) 'Bench to behavior ': translating comparative effectiveness research into improved clinical practice. Health Aff (Millwood) 29:1891-1900
59. Larsen MD, Cars T, Hallas J (2013) A minireview of the use of hospital-based databases in observational inpatient studies of drugs. Basic Clin Pharmacol Toxicol 112:13-18
60. Gillström A, Wettermark B for the Scientific Committee of the ISPE/EuroDurg meeting in Antwerp (2011). Literature review. Cross-national comparison of DU activities. Publication from the European scientific meeting of Drug Utilization " Better public health through pharmacoepidemiology and quality use of medicine", Antwerp, Belgium 2011. Available from: http://www.pharmacoepi.org/eurodurg/workgr/Report-CNC-Literature-review.pdf. Accessed 20 Feb 2013
61. Wettermark B, Persson ME, Wilking N, Kalin M, Korkmaz S, Hjemdahl P, Godman B, Petzold M, Gustafsson LL, for the Regional Drug Expert Consortium (2010) Forecasting drug use and expenditures in a metropolitan health region. BMC Health Serv Res 10:128. doi:10.1186/1472-6963-10-128
62. Truffer CJ, Keehan S, Smith S, Cylus J, Sisko A, Poisal JA, Lizonitz J, Clemens MK (2010) Health spending projections through 2019: the recession 's impact continues. Health Aff (Millwood) 29:522-529
63. Kaplan W, Laing R (2004) Priority medicines for Europe and the world project. "A public health approach to innovation". World Health Organization, Geneva
64. Verhamme K, Sturkenboom M (2011) Study designs in paediatric pharmacoepidemiology. Eur J Clin Pharmacol 67[Suppl 1[:67-74
65. European Commission (2010). Directorate General for Employment, Social Affairs and Inclusion and Eurostat. Demography report 2010- older, more numerous and diverse Europeans (20/05/2011) Available from: http://ec.europa.eu/social/ main.jsp?catId=738&langId=en&pubId=5936&furtherPubs=yes. Accessed 27 Jan 2013
66. Doerr-MacEwen NA, Haight ME (2006) Expert stakeholders' views on the management of human pharmaceuticals in the environment. Environ Manag 38:853-866 (Pubitemid 44526854)
67. Rahman SZ, Khan RA, Gupta V, Uddin M (2007) Pharmacoenvironmentology-a component of pharmacovigilance. Environ Health 6:20
68. Beauchamp TL, Childres JF (1989) Principles of biomedical ethics, 3rd edn. Oxford University Press, New York
69. Merz JF (ed) (2001) A survey of international ethics practices in pharmacoepidemiology and drug safety. Pharmacoepidemiol Drug Saf 10:577-708
70. European Commission (2012). Proposal for a regulation of the European parliament and of the council on the protection of individuals with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation) Available from: http://ec.europa.eu/justice/data- protection/document/review2012/com-2012-11-en.pdf. Accessed 10 Feb 2013
71. Wray R (2009) Internet data heads for 500 billion gigabytes. The Guardian, May 18, 2009
72. Discovery Institute (2008) Discovery Institute 's Technology and Democracy Project (January 29, 2008). Discovery Institute, Seattle
73. Eiermann B,Bastholm-Rahmner P, Korkmaz S, Lilja B, Veg A, Wettermark B, Gustafsson LL (2009)Knowledge databases for clinical decision support in drug prescribing-development, quality assurance, management, integration, implementation and evaluation of clinical value. In: Chiang S. Jao (ed) Clinical decision support. InTech, Vienna
74. Strom BS (1995) Pharmacoepidemiology: response to the challenge. Pharmacoepidemiol Drug Saf 4:11-14